Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Researchers find that human eye can sense invisible infrared light under certain conditions

Any science textbook will tell you we can't see infrared light. Like X-rays and radio waves, infrared light waves are outside the visual spectrum.

2 Dec 2014

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Well-trained nurse practitioners can successfully provide an injection service for the treatment of wet age-related macular degeneration with ranibizumab, an audit shows.

1 Dec 2014

Second treated eyes with nAMD functionally more important than first eyes

A real-world study of the characteristics of second treated eyes in patients with neovascular age-related macular degeneration given ranibizumab in the UK National Health Service has shown that these eyes start off with better baseline visual acuity than first treated eyes and, despite a poor response to therapy, maintain this advantage.

1 Dec 2014

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report.

1 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.

27 Nov 2014

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.

20 Nov 2014

Scientists identify new factor behind major causes of blindness

Scientists at The University of Manchester have identified an important new factor behind one of the major causes of blindness, which they hope could lead to new treatments.

14 Nov 2014

Prosthetic retina could help counter the effects of AMD and related vision disorders

The loss of eyesight, often caused by retinal degeneration, is a life-altering health issue for many people, especially as they age.

13 Nov 2014

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

One of the leading causes of blindness worldwide could be detected by how our eyes respond to watching TV according to a new study from researchers at City University London.

11 Nov 2014

Sulindac drug can protect against oxidative damage due to AMD

While oxygen is essential to our planet's life force and the way we function and stay healthy, high concentrations referred to as oxidative stress may very well be the cause of more than 70 widely-spread diseases such as cancer, heart disease, neurodegenerative diseases, and eye diseases including macular degeneration.

11 Nov 2014

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.

11 Nov 2014

Stanford scientists find new way to predict progression of AMD

Stanford University School of Medicine scientists have found a new way to forecast which patients with age-related macular degeneration are likely to suffer from the most debilitating form of the disease.

6 Nov 2014

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older.

14 Oct 2014

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).

8 Oct 2014

Three institutions collaborate to study genetics of bipolar disorder, schizophrenia

Researchers at the University of Michigan School of Public Health and Medical School and collaborators at two other institutions will undertake the largest whole genome sequencing study funded to date, as they seek to better understand bipolar disorder and schizophrenia.

30 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

Envision Conference 2014 kicks off with presentation of two prestigious awards

Envision announced today that Second Sight Medical Products, Inc., a San Fernando Valley, Calif.-based medical device manufacturer, and Janet Sunness, M.D., Medical Director of Richard E. Hoover Low Vision Rehabilitation Services at Greater Baltimore Medical Center in Towson, Md., were named the 2014 recipients, respectively, of the Envision Oculus Award and Envision Award in Low Vision Research, two prestigious honors acknowledging substantial contributions to furthering research and facilitating collaborative efforts toward addressing low vision and the conditions that cause it.

19 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014